Skip to main content
Journal cover image

Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab.

Publication ,  Journal Article
Millward, PM; Bandarenko, N; Chang, PP; Stagg, KF; Afenyi-Annan, A; Hay, SN; Brecher, ME
Published in: Transfusion
September 2005

BACKGROUND: Treatment of thrombotic thrombo-cytopenia purpura (TTP) with daily therapeutic plasma exchange (TPE) may be accompanied by a variety of adjunctive interventions including most recently rituximab. Rituximab, a murine and human monoclonal antibody directed against CD20 antigen on B lymphocytes, is primarily used for treatment of non-Hodgkin's lymphomas. Because of severe and fatal infusion reactions including heart failure, rituximab carries a boxed warning. CASE REPORT: A 20-year-old female presented with TTP. She underwent 17 daily (1 day skipped) TPE. Her platelet (PLT) count reached 150 x 10(9) per L and then gradually declined to 36 x 10(9) per L despite continuing TPE. Because of the refractory behavior of her disease, rituximab was administered. After the rituximab infusion, she developed a nonproductive cough which progressed to a productive cough, acute respiratory failure, chest pain, and hypotension and was moved to intensive care for management of biventricular cardiogenic shock (ejection fraction was 5%-10%). Once stable in the intensive care unit, TPE was resumed. Her PLT count reached 241 x 10(9) per L, and her lactate dehydrogenase decreased to normal after four TPEs. Her heart failure completely resolved and she was discharged. Rituximab was added to her medical record as a drug allergy. CONCLUSION: Refractory TTP has been reported to respond favorably to rituximab when used as an adjunct. Interventions, however, can also carry significant risk as illustrated by the cardiogenic shock in our patient. Use of rituximab for refractory TTP should follow a careful assessment of benefits.

Duke Scholars

Published In

Transfusion

DOI

ISSN

0041-1132

Publication Date

September 2005

Volume

45

Issue

9

Start / End Page

1481 / 1486

Location

United States

Related Subject Headings

  • Shock, Cardiogenic
  • Rituximab
  • Purpura, Thrombotic Thrombocytopenic
  • Platelet Count
  • Immunologic Factors
  • Humans
  • Female
  • Cardiovascular System & Hematology
  • Antibodies, Monoclonal, Murine-Derived
  • Antibodies, Monoclonal
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Millward, P. M., Bandarenko, N., Chang, P. P., Stagg, K. F., Afenyi-Annan, A., Hay, S. N., & Brecher, M. E. (2005). Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab. Transfusion, 45(9), 1481–1486. https://doi.org/10.1111/j.1537-2995.2005.00560.x
Millward, P. M., N. Bandarenko, P. P. Chang, K. F. Stagg, A. Afenyi-Annan, S. N. Hay, and M. E. Brecher. “Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab.Transfusion 45, no. 9 (September 2005): 1481–86. https://doi.org/10.1111/j.1537-2995.2005.00560.x.
Millward PM, Bandarenko N, Chang PP, Stagg KF, Afenyi-Annan A, Hay SN, et al. Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab. Transfusion. 2005 Sep;45(9):1481–6.
Millward, P. M., et al. “Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab.Transfusion, vol. 45, no. 9, Sept. 2005, pp. 1481–86. Pubmed, doi:10.1111/j.1537-2995.2005.00560.x.
Millward PM, Bandarenko N, Chang PP, Stagg KF, Afenyi-Annan A, Hay SN, Brecher ME. Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab. Transfusion. 2005 Sep;45(9):1481–1486.
Journal cover image

Published In

Transfusion

DOI

ISSN

0041-1132

Publication Date

September 2005

Volume

45

Issue

9

Start / End Page

1481 / 1486

Location

United States

Related Subject Headings

  • Shock, Cardiogenic
  • Rituximab
  • Purpura, Thrombotic Thrombocytopenic
  • Platelet Count
  • Immunologic Factors
  • Humans
  • Female
  • Cardiovascular System & Hematology
  • Antibodies, Monoclonal, Murine-Derived
  • Antibodies, Monoclonal